MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$58,524K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities and sal...
Expense associated with license ...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Payments associated with license...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-100,703
-99,111
-108,039
-103,433
Depreciation and amortization
1,350
1,363
1,266
1,374
Stock-based compensation expense
15,941
15,541
14,124
12,377
Net accretion of discount on marketable securities
1,127
1,144
1,753
1,674
Gain on sale of contingent payments
-
-
0
0
Loss on disposal of property and equipment
0
-
299
-299
Non-cash operating lease expense
3,321
3,258
3,196
3,135
Expense associated with license agreement
25,000
-
0
0
Realized gain on investments
67
28
118
-2
Milestone payment from gain on sale of oncology business
-
-
0
0
Accounts receivable, net
3,980
5,555
5,548
43
Inventory
-4,935
2,167
886
1,186
Contract assets
4,104
-
-
-
Prepaid expenses and other current and non-current assets
4,888
2,456
945
-1,519
Accounts payable
3,080
-4,993
-1,145
1,807
Accrued expenses and other current liabilities
8,354
-19,166
8,242
1,928
Income taxes payable
0
0
0
0
Operating lease liabilities
-4,574
-4,462
-4,308
-4,245
Other liabilities
-
-
-790
-
Other non-current liabilities
940
-
-
-11
Net cash used in operating activities
-57,312
-118,920
-96,213
-88,151
Purchases of marketable securities
151,571
148,182
161,078
174,981
Proceeds from maturities and sales of marketable securities
217,993
290,263
252,274
272,091
Proceeds from sale of contingent payments
-
-
0
0
Proceeds from milestone payment from gain on sale of oncology business
-
-
0
0
Payments associated with license agreement
25,000
-
0
0
Purchases of property and equipment
1,212
769
1,120
1,555
Proceeds from sale of equipment
-
-
0
0
Net cash provided by investing activities
40,210
141,312
90,076
95,555
Net proceeds from stock option exercises and employee stock purchase plan
3,149
2,078
2,557
4,435
Net cash provided by financing activities
3,149
2,078
2,557
4,435
Net change in cash and cash equivalents
-13,953
24,470
-3,580
11,839
Cash and cash equivalents at beginning of the period
113,600
89,130
92,710
76,247
Cash and cash equivalents at end of the period
99,647
113,600
89,130
92,710
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
and sales of...
$217,993K
(-57.16%↓ Y/Y)
Net proceeds from
stock option...
$3,149K
(87.00%↑ Y/Y)
Net cash provided by
investing activities
$40,210K
(-79.01%↓ Y/Y)
Net cash provided by
financing activities
$3,149K
(87.00%↑ Y/Y)
Canceled cashflow
$177,783K
Net change in cash
and cash...
-$13,953K
(-401.75%↓ Y/Y)
Canceled cashflow
$43,359K
Expense associated with
license agreement
$25,000K
(150.00%↑ Y/Y)
Stock-based compensation
expense
$15,941K
(-38.81%↓ Y/Y)
Accrued expenses and
other current...
$8,354K
(172.19%↑ Y/Y)
Inventory
-$4,935K
(-252.69%↓ Y/Y)
Non-cash operating lease
expense
$3,321K
(-45.50%↓ Y/Y)
Accounts payable
$3,080K
(184.13%↑ Y/Y)
Depreciation and
amortization
$1,350K
(-46.79%↓ Y/Y)
Other non-current
liabilities
$940K
(220.67%↑ Y/Y)
Purchases of marketable
securities
$151,571K
(-50.42%↓ Y/Y)
Payments associated with
license agreement
$25,000K
(150.00%↑ Y/Y)
Purchases of property and
equipment
$1,212K
(-26.14%↓ Y/Y)
Net cash used in
operating activities
-$57,312K
(69.61%↑ Y/Y)
Canceled cashflow
$62,921K
Net loss
-$100,703K
(49.98%↑ Y/Y)
Prepaid expenses and
other current and...
$4,888K
(30.49%↑ Y/Y)
Operating lease
liabilities
-$4,574K
(44.41%↑ Y/Y)
Contract assets
$4,104K
Accounts receivable, net
$3,980K
(353.82%↑ Y/Y)
Net accretion of
discount on marketable...
$1,127K
(-70.09%↓ Y/Y)
Realized gain on
investments
$67K
(3250.00%↑ Y/Y)
Buy us a coffee
AGIOS PHARMACEUTICALS, INC. (AGIO)
AGIOS PHARMACEUTICALS, INC. (AGIO)